DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 12, 2008; DOI: 10.1124/dmd.108.020909


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.020909v1
36/9/1917    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Takeda, S.
Right arrow Articles by Watanabe, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeda, S.
Right arrow Articles by Watanabe, K.


Received for publication February 12, 2008.
Revised June 5, 2008.
Accepted for publication June 10, 2008.

Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis

Shuso Takeda 1, Koichiro Misawa 1, Ikuo Yamamoto 2, Kazuhito Watanabe 1*

1 Hokuriku University 2 Kyushu University of Health and Welfare

* Address correspondence to: E-mail: k-watanabe{at}hokuriku-u.ac.jp

Abstract

ABSTRACT: In the present study it was revealed that cannabidiolic acid (CBDA) selectively inhibited cyclooxygenase-2 (COX-2) activity with an IC50 value (50% inhibition concentration) around 2 µM, having 9-fold higher selectivity than COX-1 inhibition. In contrast,{Delta}9-tetrahydrocannabinolic acid ({Delta}9-THCA) was a much less potent inhibitor of COX-2 (IC50 >> 100 µM). Nonsteroidal anti-inflammatory drugs containing a carboxyl group in their chemical structures such as salicylic acid are known to inhibit nonselectively both COX-1 and COX-2. CBDA and {Delta}9-THCA have a salicylic acid moiety in their structures. Thus, the structural requirements for the CBDA-mediated COX-2 inhibition were next studied. There is a structural difference between CBDA and {Delta}9-THCA; phenolic hydroxyl groups of CBDA are freed from the ring formation with the terpene moiety, although {Delta}9-THCA has dibenzopyran ring structure. It was assumed that the whole structure of CBDA is important for COX-2 selective inhibition, since {beta}-resorcylic acid itself did not inhibit COX-2 activity. Methylation of the carboxylic acid moiety of CBDA led to disappearance of COX-2 selectivity. Thus, it was suggested that the carboxylic acid moiety in CBDA is a key determinant for the inhibition. Further, the crude extract of cannabis containing mainly CBDA was shown to have a selective inhibitory effect on COX-2. Taken together, these lines of evidence in this study suggest that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2.


Key words: cannabinoids, cyclooxygenases, enzyme inhibitors





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.